Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis.

Published on Feb 5, 2021in Journal of Clinical Apheresis1.629
· DOI :10.1002/JCA.21881
Charan Thej Reddy Vegivinti1
Estimated H-index: 1
(Manipal University),
John M. Pederson2
Estimated H-index: 2
+ 25 AuthorsAmeer E Hassan23
Estimated H-index: 23
The purpose of this systematic review and meta-analysis was to examine clinical outcomes associated with convalescent plasma therapy in COVID-19 patients. We performed a literature search on PubMed, medRxiv, Web of Science, and Scopus to identify studies published up to December 10th, 2020 that examined the efficacy of convalescent plasma treatment for COVID-19. The primary endpoints were mortality, clinical improvement, and hospital length of stay. We screened 859 studies that met the search criteria, performed full-text reviews of 56 articles, and identified 15 articles that fulfilled inclusion criteria for meta-analysis. The odds of mortality were significantly lower in the convalescent plasma group compared to the control group (OR = 0.59 [95% CI = 0.44; 0.78], P < .001), although results from two key randomized controlled trials did not support the mortality benefit. The odds of clinical improvement were significantly higher in the convalescent plasma group compared to the control group (OR = 2.02 [95% CI = 1.54; 2.65], P < .001). There was no difference in hospital length of stay between the convalescent plasma group and the control group (MD = -0.49 days [95% CI = -3.11; 2.12], P = .713). In all, these data indicate that a mortality benefit with convalescent plasma is unclear, although there remain benefits with convalescent plasma therapy for COVID-19.
#1Ali S. OmraniH-Index: 16
#2Ahmed Zaqout (Hamad Medical Corporation)H-Index: 3
Last. Abdullatif Al-Khal (Hamad Medical Corporation)H-Index: 8
view all 21 authors...
BACKGROUND: The role of convalescent plasma therapy for patients with coronavirus disease 2019 (COVID-19) is unclear. METHODS: We retrospectively compared outcomes in a cohort of critical COVID-19 patients who received standard care (SC Group) and those who, in addition, received convalescent plasma (CP Group). RESULTS: In total, 40 patients were included in each group. The median patient age was 53.5 years (interquartile range [IQR] 42-60.5), and the majority of patients required invasive venti...
17 CitationsSource
#1Ventura A Simonovich (Hospital Italiano de Buenos Aires)H-Index: 3
Last. Waldo H. BellosoH-Index: 17
view all 39 authors...
Background Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials. Methods We randomly assigned hospitalized adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome was the patient's clinical status 30 days after the intervention, as me...
284 CitationsSource
#2Mariam AyedH-Index: 3
Last. Medhat Z. Askar (Texas A&M Health Science Center College of Medicine)H-Index: 1
view all 23 authors...
Objective To study the effectiveness of CCP therapy for moderate and severe COVID-19 disease patients in Kuwait. Methods This non-randomized prospective cohort study was conducted from May 21, 2020, to June 30, 2020, at four major tertiary hospitals in Kuwait. CCP was administered to 135 patients. The control group comprised 233 patients who received standard treatment. All patients (N = 368, median age 54 [range 15-82] years) had laboratory-confirmed SARS-CoV-2 infection and either moderate or ...
7 CitationsSource
#1Fevzi Altuntas (UHSA: University of Health Sciences Antigua)H-Index: 18
#2Naim AtaH-Index: 2
Last. Osman Tayyar ÇelikH-Index: 5
view all 22 authors...
INTRODUCTION: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19. METHOD: The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched se...
28 CitationsSource
#1Eric Salazar (Cornell University)H-Index: 14
#2Paul A. Christensen (Houston Methodist Hospital)H-Index: 11
Last. James M. Musser (Cornell University)H-Index: 121
view all 19 authors...
Coronavirus disease 2019 (COVID-19) convalescent plasma has emerged as a promising therapy and has been granted Emergency Use Authorization by the US Food and Drug Administration for hospitalized COVID-19 patients. We recently reported results from interim analysis of a propensity score-matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high-titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality. We herein ...
51 CitationsSource
#1Xiaoli Wang (Capital Medical University)H-Index: 6
#2Xianghua Guo (Capital Medical University)H-Index: 9
Last. Quanyi Wang (Capital Medical University)H-Index: 11
view all 9 authors...
BACKGROUND Coronavirus disease 2019 (COVID-19) is a pandemic with no specific antiviral treatments or vaccines. There is an urgent need for exploring the neutralizing antibodies from patients with different clinical characteristics. METHODS A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. Antibodies were determined with a modified cytopathogenic neutralization assay (NA) based on live severe acute respiratory syndrome coronavirus 2 and enzyme-lin...
133 CitationsSource
#1Anup Agarwal (ICMR: Indian Council of Medical Research)H-Index: 8
#2Aparna Mukherjee (ICMR: Indian Council of Medical Research)H-Index: 16
Last. Pankaj Malhotra (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 20
view all 6 authors...
Abstract Objective To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm, phase II, multicentre, randomised controlled trial. Setting 39 public and private hospitals across India. Participants 464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/...
264 CitationsSource
#1Ralph Rogers (Brown University)H-Index: 5
#2Fadi Shehadeh (Brown University)H-Index: 9
Last. Eleftherios Mylonakis (Brown University)H-Index: 83
view all 12 authors...
Background The efficacy of convalescent plasma (CP) for the treatment of COVID-19 remains unclear. Methods In a matched cohort analysis of hospitalized patients with severe COVID-19, the impact of CP treatment on in-hospital mortality was evaluated using univariate and multivariate Cox proportional-hazards models, and the impact of CP treatment on time to hospital discharge was assessed using a stratified log-rank analysis. Results 64 patients who received CP a median of 7 days after symptom ons...
21 CitationsSource
#1Sean T. H. Liu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 14
#2Hung-Mo Lin (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 24
Last. Nicole M. Bouvier (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 29
view all 30 authors...
219 CitationsSource
#1Anwar M. RasheedH-Index: 3
#2Dhurgham F FatakH-Index: 1
Last. Ahmed Sahib AbdulamirH-Index: 23
view all 7 authors...
The current COVID-19 pandemic needs unconventional therapies to tackle the resulted high morbidity and mortality. Convalescent plasma is one of the therapeutic approaches that might be of benefit. Forty nine early-stage critically-ill COVID-19 patients residing in Respiratory Care Units (RCU) of three hospitals in Baghdad, Iraq, were included: 21 received convalescent plasma while 28, namely control group, did not receive it. Recovery or death, length of stay in hospital, and improvement in the ...
37 Citations
Cited By3
#2Hayder Chasib Assad (University of Kufa)H-Index: 1
Last. Hayder Adnan Fawzi (Al Rasheed University College)
view all 3 authors...
Background: As an effective antiviral therapy is not available for the treatment of the current rapidly and continuously spreading coronavirus disease (COVID-19), it is very crucial to find an alternative treatment strategy. Convalescent plasma (CP) therapy has been used for prevention and treatment of many emerging infectious diseases, however, the results of current studies on CP in COVID-19 are not consistent. Therefore, this study aimed to evaluate the effectiveness of CP therapy in hospital...
#1Donald C. Vinh (MUHC: McGill University Health Centre)H-Index: 31
#2Laurent Abel (University of Paris)H-Index: 112
Last. Pere Soler-Palacín (Autonomous University of Barcelona)H-Index: 24
view all 18 authors...
D.C.V. is supported by the Fonds de la recherche en sante du Quebec clinician-scientist scholar Junior 2 program. L.D.N. and H.C.S. are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the Nati...
Abstract Background Convalescent plasma (CP) has been used in the past in various pandemics, in particular in H1N1, SARS and MERS infections. In Spring 2020, when ongoing the SARS-CoV-2 pandemics, the Veneto Region (V-R) has proposed setting-up an anti-SARS-CoV-2 CP (CCP) Bank, with the aim of preparing a supply of CCP immediately available in case of subsequest epidemic waves. Materials and Methods Key-points to be developed for a quick set-up of the V-R CCP Bank have been recruitment of donors...
1 CitationsSource